SAN FRANCISCO and SUZHOU, China, June 4, 2026
Innovent Biologics has announced a major breakthrough in precision oncology as its investigational antibody-drug conjugate (ADC) arcotatug tavatecan (IBI343) successfully achieved the primary endpoint in the international Phase III G-HOPE-001 clinical trial for advanced gastric and gastroesophageal junction adenocarcinoma. The positive interim analysis results have paved the way for regulatory advancement, with the National Medical Products Administration (NMPA) of China accepting the New Drug Application (NDA) under priority review. The milestone positions IBI343 as the world’s first CLDN18.2-targeted ADC to enter regulatory review, highlighting the growing role of biomarker-driven precision medicine in addressing significant unmet needs among patients with advanced gastrointestinal cancers.
Phase III Trial Demonstrates Strong Clinical Benefit
The international, multicenter, randomized G-HOPE-001 Phase III study evaluated arcotatug tavatecan as a monotherapy in patients with previously treated CLDN18.2-positive locally advanced unresectable or metastatic gastric or gastroesophageal junction adenocarcinoma who had received at least two prior systemic therapies. Conducted across China and Japan, the trial compared IBI343 against investigator-selected standard therapies and successfully met its primary endpoint during the first interim analysis.
The study demonstrated excellent efficacy alongside a manageable safety profile, reinforcing the therapeutic potential of CLDN18.2-targeted treatment strategies. Patients with advanced gastric cancer often face rapid disease progression and limited treatment options following multiple lines of therapy, with median survival typically remaining around six months. The positive Phase III results therefore represent a significant advancement for a patient population with substantial unmet medical needs and limited therapeutic alternatives.
First CLDN18.2 ADC Advances Toward Regulatory Approval
Advertisement
Arcotatug tavatecan is a next-generation CLDN18.2-targeted antibody-drug conjugate engineered to selectively deliver a potent topoisomerase I inhibitor (TOPO1i) payload directly to cancer cells expressing CLDN18.2. The ADC utilizes a cleavable linker and incorporates Fc silencing technology designed to minimize off-target toxicities while maximizing anti-tumor activity. Once internalized by tumor cells, the cytotoxic payload induces DNA damage and triggers cell death, while also generating a beneficial bystander effect capable of targeting neighboring cancer cells.
Based on the strong efficacy and safety findings from G-HOPE-001, Innovent has submitted an NDA seeking approval for previously treated advanced CLDN18.2-positive gastric and gastroesophageal junction cancers. The application has been accepted under priority review, accelerating the regulatory pathway and bringing the therapy one step closer to patients. Importantly, IBI343 is the first CLDN18.2 ADC globally to reach this stage of regulatory review, underscoring its pioneering position within the evolving gastrointestinal oncology landscape.
Expanding Precision Oncology Beyond Gastric Cancer
The success of IBI343 reflects the growing importance of precision oncology and biomarker-guided therapies in treating difficult-to-manage cancers. CLDN18.2 is highly expressed in a large proportion of gastric and gastroesophageal cancers, making it an attractive target for innovative therapies. Beyond gastric cancer, Innovent is actively investigating arcotatug tavatecan in additional solid tumors, including pancreatic cancer, where the candidate is currently being evaluated in a Phase III study in China. The therapy is also being studied in earlier-stage clinical trials exploring first-line treatment opportunities and combination strategies.
Further strengthening its global development potential, Innovent entered into a strategic partnership with Takeda in 2025, granting the company exclusive rights to develop and commercialize IBI343 outside Greater China. As the oncology industry continues to embrace targeted therapeutics and ADC innovation, arcotatug tavatecan is emerging as one of the most promising next-generation treatments for CLDN18.2-positive cancers and could establish a new standard of care for patients with advanced gastric malignancies.
Source: Innovent Biologics press release
